Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study

2004 ◽  
Vol 57 (3) ◽  
pp. 294-300 ◽  
Author(s):  
J.D Hooi ◽  
A.D.M Kester ◽  
H.E.J.H Stoffers ◽  
P.E.L.M Rinkens ◽  
J.A Knottnerus ◽  
...  
2013 ◽  
Vol 12 (2) ◽  
pp. 91-101
Author(s):  
Leonardo Ghizoni Bez

BACKGROUND: Endovascular treatment of peripheral arterial occlusive disease has become increasingly frequent in the past few years. Because it is a less invasive procedure, lower morbidity and mortality rates are associated with this form of treatment. OBJECTIVES: To describe the endovascular procedures performed in iliac arteries for the treatment of peripheral arterial occlusive disease. METHODS: This retrospective study assesses 59 cases of iliac artery angioplasty performed according to a specific protocol from January 2004 to February 2010. RESULTS: Mean age of patients was 62 years (minimum: 42, maximum: 89). Thirty seven were male (62.72%) and 22 female (37.28%). The main indications for treatment were moderate to severe intermittent claudication in 30 cases (50.84%) and rest pain or trophic lesions (critical ischemia) in 29 cases (49.15%). Postoperative follow-up included ankle-brachial index measurements and a duplex ultrasound at 30 days, 3 months, 6 months, 12 months, and every 6 months thereafter. Minimum follow-up time was 3 months, and maximum, 72 months (6 years), with primary and secondary patency rates of 91.37 and 94.82%, respectively. CONCLUSIONS: The results of this case series, combined with literature review results, allow to conclude that the endovascular approach is an effective and safe option to treat peripheral arterial occlusive disease in iliac arteries.


2009 ◽  
Vol 88 (10) ◽  
pp. 979-988 ◽  
Author(s):  
Birgit Linnemann ◽  
Stephanie Prochnow ◽  
Helen Mani ◽  
Jan Schwonberg ◽  
Edelgard Lindhoff-Last

VASA ◽  
2004 ◽  
Vol 33 (3) ◽  
pp. 137-144 ◽  
Author(s):  
Creutzig ◽  
Lehmacher ◽  
Elze

Background: The relevance of Prostaglandin E1 (PGE1) in the treatment of peripheral arterial occlusive disease stage III and IV was to be evaluated for the first time by a meta-analysis. Patients and methods: Altogether, 643 patients were analyzed from seven randomized, controlled PGE1 studies that were comparable with regard to patient selection, study design and endpoints. Of these, only placebo-controlled studies (n = 254) were included in the formal meta-analysis using the method of DerSimonian and Laird. Additionally, the response rate and the rate of adverse events were determined for the pooled groups of all studies. Results: At the end of treatment, PGE1 showed a significantly better response (ulcer healing and/or pain reduction) as compared to placebo (47.8% for PGE1 vs. 25.2% for placebo, p = 0.0294). A significant difference in favor of PGE1 was also seen for the combined endpoint “major amputation or death” after 6-month follow-up (22.6% for PGE1 vs. 36.2% for placebo, p = 0.0150). The response rate (ulcer healing and/or pain relief) of the pooled treatment groups was 60.2% for PGE1, 25.2% for placebo, and 53.6% for iloprost. The adverse events rate of the pooled treatment groups showed good tolerability for PGE1 with a rate of 39.6% in comparison to 73.9% for iloprost and 15.4% for placebo. Conclusion: For patients with peripheral arterial occlusive disease stage III or IV not eligible for arterial reconstruction, PGE1 therapy not only has significant beneficial effects over placebo on ulcer healing and pain relief, but also increases the rate of patients surviving with both legs after 6-months follow-up.


Sign in / Sign up

Export Citation Format

Share Document